SWX Reports Successful Stock Market Debut Of Actelion

Actelion Ltd, ninth company to list on SWX New Market, opens 92% above offering price. The shares of Actelion Ltd., a bio-pharmaceutical company, were traded today for the first time on the SWX New Market. The offering price was set Wendsday night at CHF 260. At the start of trading on SWX, the stock stood 92% above that level at CHF 500, representing a total market capitalization for the company of CHF 2,4 billion.

According to the offering prospectus, of the 4,733,860 registered shares shown in the Commercial Register, 900,000, or 19% of the company's outstanding stock, were offered to the public. Should the underwriters elect to exercise their green-shoe option, that proportion could rise to 21%.

Actelion Ltd. with its headquarter in Allschwil (Switzerland), is a bio-pharmaceutical company aiming to bring innovative drugs to the market through science related to Endothelium. Actelion Ltd. founded in 1997 employs 90 individuals and recorded a net revenue of CHF 2,9 million in 1999. The bio-pharmaceutical company maintains subsidiaries in USA, Germany and Israel.